In percutaneous coronary intervention (PCI), the concept of securing metal free angioplasty without leaving behind a permanent foreign body is highly attractive to patients and physicians and promises several advantages. However, target lesion failure and device thrombosis were important concerns with first-generation Bioresorbable scaffolds (BRS) leading to low rates of adoption in clinical practice (1-12). New iterations, incorporating improvements such as a smaller strut thickness have been proposed and evaluated in early investigations. However, it remains unclear whether these modifications are sufficient to achieve outcomes comparable to those of metallic drug-eluting stents (DES) while preserving the benefits of resorption (10-12).
Author Sub-editor: Dr Pok-Tin Tang Dr Pok-Tin Tang is an ST5 cardiology registrar in the Thames Valley deanery, currently undertaking a period of out of
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
Author Sub-editor: Dr Atmadeep Banerjee Dr Atmadeep Banerjee is an ST4 Cardiology Registrar in the Kent, Surrey and Sussex deanery. He graduated from Calcutta National
